28478-47-9

Upstream product

• 67-56-1 methanol 
• 7206-70-4 4-amino-5-chloro-2-methoxybenzoic acid 
• 75-36-5 acetyl chloride 
• 28478-45-7 methyl 4-benzyloxy-2-methoxybenzoate 
• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 5427-29-2 methyl 2-hydroxy-4-benzyloxybenzoate 
• 28478-46-8 methyl 4-hydroxy-2-methoxybenzoate 
• 86720-98-1 5-chloro-4-hydroxy-2-methoxybenzoic acid 

Downstream Products

• 1154415-30-1 tert-butyl 4-[2-chloro-5-methoxy-4-(methoxycarbonyl)phenoxy]piperidine-1-carboxylate 
• 28478-48-0 N-(1-ethyl-2-pyrrolidylmethyl)-2-methoxy-4-hydroxy-5-chlorobenzamide hydrochloride 
• 1346763-27-6 2-chloro-4-(hydroxymethyl)-5-methoxyphenol 
• 1346763-29-8 [4-(3-bromopropoxy)-5-chloro-2-methoxyphenyl]methanol 
• 1346764-93-9 [4-(4-bromobutoxy)-5-chloro-2-methoxyphenyl]methanol 
• 1435516-74-7 [2-chloro-4-(hydroxymethyl)-5-methoxyphenoxy]acetic acid 
• 1435516-73-6 ethyl [2-chloro-4-(hydroxymethyl)-5-methoxyphenoxy]acetate 
• 1346763-34-5 trans-4-[[3-(2-chloro-4-formyl-5-methoxyphenoxy)propyl](methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346763-32-3 trans-4-[{3-[2-chloro-4-(hydroxymethyl)-5-methoxyphenoxy]propyl}(methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 

Relevant academic research and scientific papers

NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

BENZAMIDE DERIVATIVES

A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R1, R2, R3 and R4, which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na+/H+ exchange transport system caused by the Rho kinase inhibition, for example, hypertension.

Methods of protection against emesis in mammals by administration of a heterocyclic benzamide

The heterocyclic benzamides of this invention are particularly effective for the treatment of emesis in mammals. For example, when they are administered to dogs in relatively small dosage, they afford 100% protection against vomiting. They are also non-toxic in dosages for effecting complete control of vomiting.